FDA backs Roche's Gazyva in first-line follicular lymphoma
ZURICH (Reuters) - The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma, bolstering the Swiss drugmaker's efforts to strengthen its portfolio of blood cancer medicines.
from Reuters: Health News http://ift.tt/2j1rkNX
November 16, 2017
|
Labels:
IFTTT,
Reuters: Health News
|
This entry was posted on November 16, 2017
and is filed under
IFTTT
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.